Management of Resistant Hypertension

Current Blood Pressure Assessment

The American Heart Association recommends that patients with Stage 2 systolic hypertension, despite being on maximum-dose telmisartan (80 mg) with hydrochlorothiazide (12.5 mg), should have their blood pressure assessed and therapy intensified promptly, as the systolic BP is 40-50 mmHg above the recommended target of 120-129 mmHg 1
The European Society of Cardiology states that this degree of elevation requires prompt intensification of therapy 2

The European Society of Cardiology recommends adding a dihydropyridine calcium channel blocker, such as amlodipine 5-10 mg daily, to create a triple therapy regimen, as this represents the preferred combination for resistant hypertension and will provide the most effective blood pressure reduction 1, 2
The American College of Cardiology suggests that the combination of ARB (telmisartan) + thiazide diuretic (hydrochlorothiazide) + dihydropyridine calcium channel blocker represents the preferred triple therapy for resistant hypertension, providing complementary mechanisms of action: RAS blockade, sodium depletion, and vasodilation 2, 1

The American Heart Association recommends considering switching hydrochlorothiazide 12.5 mg to chlorthalidone 12.5-25 mg daily, as chlorthalidone is superior to hydrochlorothiazide for blood pressure control and cardiovascular outcomes 4
The European Society of Cardiology suggests that adding a mineralocorticoid receptor antagonist, such as spironolactone 12.5-25 mg daily, provides significant additional blood pressure reduction when added to multidrug regimens including an ARB and diuretic 3

The American College of Cardiology recommends rechecking blood pressure in 2-4 weeks after any medication adjustment, and monitoring electrolytes (potassium, sodium, calcium) within 2-4 weeks of adding or switching diuretics 1, 4
The European Society of Cardiology suggests assessing renal function (creatinine, eGFR) within 2-4 weeks, and checking uric acid levels if adding or increasing thiazide diuretics 1

The American Heart Association warns that combining telmisartan with an ACE inhibitor or direct renin inhibitor increases risks of hypotension, hyperkalemia, and renal dysfunction, and should be avoided 1
The European Society of Cardiology recommends using caution with mineralocorticoid receptor antagonists in patients with eGFR <45 mL/min/1.73 m² or baseline potassium >4.5 mEq/L 3

The American College of Cardiology recommends aiming for systolic BP 120-129 mmHg and diastolic BP 70-79 mmHg, and achieving target within 1-3 months of treatment intensification 1, 2
The European Society of Cardiology suggests that in patients ≥65 years, systolic BP <130 mmHg is acceptable if tolerated 1